位置:首页 > 产品库 > TC-SP 14
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
TC-SP 14
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
TC-SP 14图片
CAS NO:1257093-40-5

TC-SP 14 (compound 14) 是一种口服有效的S1P1激动剂 (EC50= 0.042 μM),在 S1P3 处活性极低 (EC50= 3.47 μM)。TC-SP 14 可显著降低血液淋巴细胞计数,减弱对抗原挑战的迟发型超敏反应(DTH)。
生物活性

TC-SP 14 (compound 14) is an orally active and potentS1P1agonist (EC50= 0.042 μM) with minimal activity at S1P3 (EC50= 3.47 μM). TC-SP 14 significantly reduces blood lymphocyte counts and attenuates a delayed type hypersensitivity (DTH) response to antigen challenge[1].

IC50& Target

S1PR1

0.042 μM (EC50)

S1PR3

3.47 μM (EC50)

体外研究
(In Vitro)

TC-SP 14 (compound 14) neither inhibits nor induces human cytochrome P450 enzymes, is nonmutagenic, and dose not significantly inhibit the hERG channel[1].

体内研究
(In Vivo)

TC-SP 14 (compound 14) (0-3 mg/kg, Orally, once) produces a dose-dependent reduction in circulating blood lymphocytes 24 h postdose[1].
TC-SP 14 (0-3 mg/kg, Orally, daily for 10 days) significant reduces ovalbumin (OVA)-induced ear swelling[1].
TC-SP 14 (2-15 mg/kg, IV or PO, once) possesses acceptable characteristics[1].
Pharmacokinetic Parameters of TC-SP 14 in female Sprague-Dawley rats and male Cynomolgus[1].

speciesratNHP
CL (L/h/kg)0.330.50
Vss (L/kg)3.31.6
T1/2(h)7.535.2
MRT (h)103.3
% F6823

Animal Model:Lewis rats (female, n = 5/group)[1]
Dosage:0.3, 1.0, and 3.0 mg/kg
Administration:Orally, once
Result:Produced a dose-dependent reduction in circulating blood lymphocytes 24 h postdose, resulted in near maximal lymphopenia at 3.0 mg/kg (74% reduction in lymphocytes vs vehicle).
Animal Model:OVA-immunized Lewis rats (female, n = 8/group)[1]
Dosage:0.1, 0.3, 1.0, and 3.0 mg/kg
Administration:Orally, daily for 10 days
Result:Significant reduced OVA-induced ear swelling at doses of 0.3 mg/kg and higher.
Animal Model:Female Sprague-Dawley rats, Male Cynomolgus (NHP (nonhuman primates)) (n=3/group)[1]
Dosage:2 (IV, rat), 4 (IV, NHP), 10 (PO, NHP), 15 mg/kg (PO, rat)
Administration:IV, PO, once (Pharmacokinetic Analysis)
Result:Possessed acceptable characteristics, demonstrated low clearance, moderate steady state volumes of distribution, moderate-to-long mean residence times, and acceptable oral bioavailability.
分子量

450.50

Formula

C25H20F2N2O2S

CAS 号

1257093-40-5

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024